Information Provided By: 
Fly News Breaks for September 20, 2017
PFE
Sep 20, 2017 | 07:24 EDT
As previously reported, Morgan Stanley analyst David Risinger upgraded Pfizer to Overweight from Equal Weight, stating that he believes investors underappreciate the global prospects for breast cancer drug Ibrance, which he expects to maintain its first-to-market advantage. Additionally, he views the stock's valuation as attractive relative to comps and history following a long period of "middling" performance. Risinger raised his price target Pfizer shares to $39 from $35.
News For PFE From the Last 2 Days
PFE
Apr 25, 2024 | 10:25 EDT
Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.
